TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has released new long-term data showing that the use of Ceplene® when administered in conjunction with low-dose interleukin-2 (IL-2) provides durable protection from leukemia relapse in patients with Acute Myeloid Leukemia (AML), based on a minimum of six years of follow-up. These data will be presented on June 6, 2009 at the European Hematology Association’s (EHA) 14th Congress in Berlin, Germany.
